{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T13:17:16Z","timestamp":1773926236845,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,12,7]],"date-time":"2005-12-07T00:00:00Z","timestamp":1133913600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1007\/s00213-005-0230-1","type":"journal-article","created":{"date-parts":[[2005,12,6]],"date-time":"2005-12-06T15:14:41Z","timestamp":1133882081000},"page":"107-114","source":"Crossref","is-referenced-by-count":17,"title":["Effects of the atypical antipsychotics olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data"],"prefix":"10.1007","volume":"184","author":[{"given":"Claire","family":"Rourke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn R.","family":"Starr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlie","family":"Reavill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Fenwick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Deadman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Declan N.C.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,12,7]]},"reference":[{"key":"230_CR1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","volume":"20","author":"M Aravagiri","year":"1999","unstructured":"Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369\u2013377","journal-title":"Biopharm Drug Dispos"},{"key":"230_CR2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00213-001-0933-x","volume":"159","author":"M Aravagiri","year":"2002","unstructured":"Aravagiri M, Marder SR (2002) Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats Psychopharmacology 159:424\u2013431","journal-title":"Psychopharmacology"},{"key":"230_CR3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0006-8993(02)03616-8","volume":"957","author":"T Baptista","year":"2002","unstructured":"Baptista T, Araujo de Baptista E, Ying Kin NM, Beaulieu S, Walker D, Joober R, Lalonde J, Richard D (2002) Comparative effects of the antipsychotics sulpiride or risperidone in rats I: bodyweight, food intake, body comparison, hormones and glucose tolerance. Brain Res 957:144\u2013151","journal-title":"Brain Res"},{"key":"230_CR4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0378-4347(01)00548-5","volume":"767","author":"M Berna","year":"2002","unstructured":"Berna M, Ackermann B, Ruterbories K, Glass S (2002) Determination of olanzapine in human blood by liquid chromatography\u2013tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 767:163\u2013168","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"230_CR5","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1176\/ajp.156.2.294","volume":"156","author":"AF Breier","year":"1999","unstructured":"Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clifton A, Pickar D (1999) Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. Am J Psychiatry 156:294\u2013298","journal-title":"Am J Psychiatry"},{"key":"230_CR6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","volume":"37","author":"JT Callaghan","year":"1999","unstructured":"Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177\u2013193","journal-title":"Clin Pharmacokinet"},{"key":"230_CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0920-9964(97)00036-4","volume":"26","author":"AM Crawford","year":"1997","unstructured":"Crawford AM, Beasley CM Jr, Tollefson GD (1997) The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 26:41\u201354","journal-title":"Schizophr Res"},{"key":"230_CR8","first-page":"A48","volume":"S17","author":"J Cropley","year":"2003","unstructured":"Cropley J, Gibson V, Rourke C, Hatcher P, Jones DNC, Reavill C (2003) Pharmacological profile of atypical antipsychotic drugs. J Psychopharmacol S17:A48","journal-title":"J Psychopharmacol"},{"issue":"Suppl 1","key":"230_CR9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00113-0","volume":"28","author":"AJ Cutler","year":"2003","unstructured":"Cutler AJ (2003) Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 28 (Suppl 1):69\u201382","journal-title":"Psychoneuroendocrinology"},{"key":"230_CR10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0149-2918(00)80086-7","volume":"22","author":"SR David","year":"2000","unstructured":"David SR, Taylor CC, Kinon BJ, Breier A (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22:1085\u20131096","journal-title":"Clin Ther"},{"issue":"Suppl","key":"230_CR11","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S0920-9964(98)00159-5","volume":"35","author":"RA Dickson","year":"1999","unstructured":"Dickson RA, Glazer WM (1999) Neuroleptic-induced hyperprolactinemia. Schizophrenia research 35 (Suppl):S75\u2013S86","journal-title":"Schizophrenia research"},{"key":"230_CR12","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/0269881104042613","volume":"18","author":"MJ Fell","year":"2004","unstructured":"Fell MJ, Marshall KM, Williams J, Neill JC (2004) Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol 18:149\u201355","journal-title":"J Psychopharmacol"},{"key":"230_CR13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbr.2004.12.015","volume":"160","author":"MJ Fell","year":"2005","unstructured":"Fell MJ, Gibson R, McDermott E, Sisodia G, Marshall KM, Neill JC (2005) Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav Brain Res 160:338\u201343","journal-title":"Behav Brain Res"},{"key":"230_CR14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/00004714-199808000-00009","volume":"18","author":"DC Goff","year":"1998","unstructured":"Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner KD, Law CG, Ko GN (1998) An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 18:296\u2013304","journal-title":"J Clin Psychopharmacol"},{"key":"230_CR15","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14656566.3.10.1381","volume":"3","author":"PJ Goodnick","year":"2002","unstructured":"Goodnick PJ, Rodriguez L, Santana O (2002) Antipsychotics: impact on prolactin levels. Expert Opin Pharmacother 3:1381\u20131391","journal-title":"Expert Opin Pharmacother"},{"key":"230_CR16","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02098500","volume":"68","author":"GA Gudelsky","year":"1987","unstructured":"Gudelsky GA, Koenig JI, Simonovic M, Koyama T, Ohmori T, Meltzer HY (1987) Differential effects of haloperidol, clozapine, and fluperlapine on tuberoinfundibular dopamine neurons and prolactin secretion in the rat. J Neural Transm 68:227\u2013240","journal-title":"J Neural Transm"},{"key":"230_CR17","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:2291\u20132314","journal-title":"Drugs"},{"issue":"Suppl 1","key":"230_CR18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0306-4530(02)00112-9","volume":"28","author":"U Halbreich","year":"2003","unstructured":"Halbreich U, Kinon BJ, Gilmore JA, Kahn LS (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28 (Suppl 1):53\u201367","journal-title":"Psychoneuroendocrinology"},{"key":"230_CR19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/10401230209147453","volume":"14","author":"M Hamner","year":"2002","unstructured":"Hamner M (2002) The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 14:163\u2013173","journal-title":"Ann Clin Psychiatry"},{"issue":"Suppl","key":"230_CR20","first-page":"13","volume":"55","author":"J Heykants","year":"1994","unstructured":"Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R (1994) The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry 55 (Suppl):13\u201317","journal-title":"J Clin Psychiatry"},{"key":"230_CR21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","volume":"54","author":"ML Huang","year":"1993","unstructured":"Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257\u2013268","journal-title":"Clin Pharmacol Ther"},{"key":"230_CR22","unstructured":"Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, Ignar DM, Jones DNC (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology. (online DOI: 10.1007\/s00213-005-0081-9)"},{"key":"230_CR23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","volume":"52","author":"S Kapur","year":"2001","unstructured":"Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503\u2013517","journal-title":"Annu Rev Med"},{"key":"230_CR24","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","volume":"302","author":"S Kapur","year":"2002","unstructured":"Kapur S, Langlois X, Vinken P, Megens AA, De Coster R, Andrews JS (2002) The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood\u2013brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302:1129\u20131134","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 2","key":"230_CR25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0306-4530(02)00128-2","volume":"28","author":"BJ Kinon","year":"2003","unstructured":"Kinon BJ, Gilmore JA, Liu H, Halbreich UM (2003) Hyperprolactinemia in response to antipsychotic drugs: characterization across comparative clinical trials. Psychoneuroendocrinology 28 (Suppl 2):69\u201382","journal-title":"Psychoneuroendocrinology"},{"key":"230_CR26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","volume":"19","author":"DL Kleinberg","year":"1999","unstructured":"Kleinberg DL, Davis JM, De Coster R, Van Baelen B, Brecher M (1999) Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19:57\u201361","journal-title":"J Clin Psychopharmacol"},{"key":"230_CR27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1677\/joe.0.0790085","volume":"79","author":"JA Mattheij","year":"1978","unstructured":"Mattheij JA, Swarts JJ (1978) Circadian variations in the plasma concentration of prolactin in the adult male rat. J Endocrinol 79:85\u201389","journal-title":"J Endocrinol"},{"key":"230_CR28","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","volume":"184","author":"AM Meaney","year":"2004","unstructured":"Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184:503\u2013508","journal-title":"Br J Psychiatry"},{"key":"230_CR29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233\u2013255","journal-title":"Schizophr Bull"},{"key":"230_CR30","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1176\/ajp.136.12.1550","volume":"136","author":"HY Meltzer","year":"1979","unstructured":"Meltzer HY, Goode DJ, Schyve PM, Young M, Fang VS (1979) Effect of clozapine on human serum prolactin levels. Am J Psychiatry 136:1550\u20131555","journal-title":"Am J Psychiatry"},{"key":"230_CR31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ps.51.2.216","volume":"51","author":"M Olfson","year":"2000","unstructured":"Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ (2000) Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 51:216\u2013222","journal-title":"Psychiatr Serv"},{"key":"230_CR32","unstructured":"Rourke C, Starr KR, Jones DNC (2004) The effect of acute and chronic administration of olanzapine on prolactin levels in rats. J Psychopharmacol S18"},{"key":"230_CR33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/0929867043456043","volume":"11","author":"A Serretti","year":"2004","unstructured":"Serretti A, De Ronchi D, Lorenzi C, Berardi D (2004) New antipsychotics and schizophrenia: a review on efficacy and side effects. Curr Med Chem 11:343\u2013358","journal-title":"Curr Med Chem"},{"key":"230_CR34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000012273","volume":"67","author":"LG Sobrinho","year":"1998","unstructured":"Sobrinho LG (1998) Emotional aspects of hyperprolactinemia. Psychother Psychosom 67:133\u2013139","journal-title":"Psychother Psychosom"},{"key":"230_CR35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2165\/00002018-200022030-00004","volume":"22","author":"C Stanniland","year":"2000","unstructured":"Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Safety 22:195\u2013214","journal-title":"Drug Safety"},{"key":"230_CR36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","volume":"154","author":"GD Tollefson","year":"1997","unstructured":"Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457\u201365","journal-title":"Am J Psychiatry"},{"key":"230_CR37","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1176\/appi.ajp.159.1.133","volume":"159","author":"P Turrone","year":"2002","unstructured":"Turrone P, Kapur S, Seeman MV, Flint AJ (2002) Elevation of prolactin levels by atypical antipsychotics. Am J Psychiatry 159:133\u2013135","journal-title":"Am J Psychiatry"},{"key":"230_CR38","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/syn.10111","volume":"46","author":"Y Yamada","year":"2002","unstructured":"Yamada Y, Ohno Y, Nakashima Y, Fukuda M, Takayanagi R, Sato H, Tsuchiya F, Sawada Y, Iga T (2002) Prediction and assessment of the extrapyramidal side effects induced by risperidone based on dopamine D2 receptor occupancy. Synapse 46: 32\u201337","journal-title":"Synapse"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-005-0230-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-005-0230-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-005-0230-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T20:01:25Z","timestamp":1683316885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-005-0230-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,7]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["230"],"URL":"https:\/\/doi.org\/10.1007\/s00213-005-0230-1","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,7]]}}}